Literature DB >> 11481358

18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer.

W B Eubank1, D A Mankoff, J Takasugi, H Vesselle, J F Eary, T J Shanley, J R Gralow, A Charlop, G K Ellis, K L Lindsley, M M Austin-Seymour, C P Funkhouser, R B Livingston.   

Abstract

PURPOSE: To determine the prevalence of suspected disease in the mediastinum and internal mammary (IM) node chain by 18fluorodeoxyglucose (FDG) positron emission tomography (PET), compared with conventional staging by computed tomography (CT) in patients with recurrent or metastatic breast cancer. PATIENTS AND METHODS: We retrospectively evaluated intrathoracic lymph nodes using FDG PET and CT data in 73 consecutive patients with recurrent or metastatic breast cancer who had both CT and FDG PET within 30 days of each other. In reviews of CT scans, mediastinal nodes measuring 1 cm or greater in the short axis were considered positive. PET was considered positive when there were one or more mediastinal foci of FDG uptake greater than the mediastinal blood pool.
RESULTS: Overall, 40% of patients had abnormal mediastinal or IM FDG uptake consistent with metastases, compared with 23% of patients who had suspiciously enlarged mediastinal or IM nodes by CT. Both FDG PET and CT were positive in 22%. In the subset of 33 patients with assessable follow-up by CT or biopsy, the sensitivity, specificity, and accuracy for nodal disease was 85%, 90%, and 88%, respectively, by FDG PET; 54%, 85%, and 73%, respectively, by prospective interpretation of CT; and 50%, 83%, and 70%, respectively, by blinded observer interpretation of CT. Among patients suspected of having only locoregional disease recurrence (n = 33), 10 had unsuspected mediastinal or IM disease by FDG PET.
CONCLUSION: FDG PET may uncover disease in these nodal regions not recognized by conventional staging methods. Future prospective studies using histopathology for confirmation are needed to validate the preliminary findings of this retrospective study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11481358     DOI: 10.1200/JCO.2001.19.15.3516

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  49 in total

Review 1.  PET/CT and breast cancer.

Authors:  Barbara Zangheri; Cristina Messa; Maria Picchio; Luigi Gianolli; Claudio Landoni; Ferruccio Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-05       Impact factor: 9.236

Review 2.  Imaging the lymphatic system: possibilities and clinical applications.

Authors:  Olivier Clément; Alain Luciani
Journal:  Eur Radiol       Date:  2004-03-09       Impact factor: 5.315

3.  Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer.

Authors:  Laura Evangelista; Zora Baretta; Lorenzo Vinante; Anna Rita Cervino; Michele Gregianin; Cristina Ghiotto; Giorgio Saladini; Guido Sotti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-30       Impact factor: 9.236

4.  Oncologic positron emission tomography: a surgical perspective.

Authors:  Todd O Moore; Landis K Griffeth
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

Review 5.  Current and future use of positron emission tomography (PET) in breast cancer.

Authors:  David A Mankoff; William B Eubank
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-04       Impact factor: 2.673

6.  Breast Cancer Treatment in the Era of Molecular Imaging.

Authors:  Gundula Edelhauser; Martin Funovics
Journal:  Breast Care (Basel)       Date:  2008-12-17       Impact factor: 2.860

Review 7.  Role of FDG PET-CT in evaluation of locoregional nodal disease for initial staging of breast cancer.

Authors:  Yiyan Liu
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Follow-up of women with breast cancer: comparison between MRI and FDG PET.

Authors:  Gerhard W Goerres; Sven C A Michel; Mathias K Fehr; Achim H Kaim; Hans C Steinert; Burkhardt Seifert; Gustav K von Schulthess; Rahel A Kubik-Huch
Journal:  Eur Radiol       Date:  2002-11-13       Impact factor: 5.315

9.  Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer.

Authors:  Tevfik F Cermik; Ayse Mavi; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-24       Impact factor: 9.236

Review 10.  The role of positron emission tomographic imaging in breast cancer.

Authors:  Michelle D McDonough; Elizabeth R DePeri; Betty A Mincey
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.